FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Related Stories
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 5 wks
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 1 month
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 1 month
BeOne’s BCL2 inhibitor gains FDA approval challenging Venclexta / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Medical Devices, Pediatric Oncology, Cancer Research and look for the RSS link.
StackHealth Time Machine